- DiaSorin’s third-quarter adjusted EBITDA was €88 million, missing the estimate of €98.7 million, and showing a year-over-year decline of 6.4%.
- The adjusted EBITDA margin decreased to 31% from 33% year-on-year.
- Total EBITDA came in at €87.0 million, also reflecting a 6.5% decline compared to the previous year.
- Revenue for the quarter was €280 million, falling short of the estimated €292.3 million and decreasing by 2.4% from last year.
- Net income dropped to €38.0 million, down 16% year-over-year, against an estimate of €44.2 million.
- For the full year of 2025, DiaSorin forecasts an adjusted EBITDA margin of about 33%, slightly lower than the previous estimate of 34.2%.
- The company has revised its full-year 2025 guidance, expecting approximately a 5% increase in revenue excluding Covid-related sales, and roughly a 4% increase when including Covid revenue (€10 million).
- Investment analyst sentiment towards DiaSorin consists of 12 buy recommendations, 3 holds, and 2 sells.
A look at DiaSorin SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
DiaSorin SpA, a company specializing in manufacturing reagents for in vitro diagnostics, shows a promising long-term outlook according to Smartkarma Smart Scores. With a solid score of 4 for Growth and Resilience, DiaSorin is positioned well for future expansion and handling market challenges. This indicates potential for sustained growth and ability to navigate through uncertainties, reflecting positively on its overall outlook.
Although DiaSorin scores lower in Momentum at 2, the company’s strengths in Value and Dividend with a score of 3 each suggest stability and attractiveness for investors looking for consistent returns. Overall, DiaSorin’s balanced scores across different factors point towards a company with good growth prospects and a reliable presence in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
